Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...
While many headline-grabbing biologics and advanced therapeutics like cell and gene therapies are approved as injectables, CDMOs Bora Pharmaceuticals and Corealis Pharma understand that oral solid | ...
In light of the strong desire to shorten timelines and lower cost for biologics such as monoclonals specially biosimilars, and address surging demand for complex proteins such as bispecific antibodies ...
See how BioDlink’s digital-intelligence platform is driving three major improvements in lyophilization workflows.
Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract ...
With the global shift toward novel biologics, next-generation biosimilars, and human-relevant, non-animal testing models, Biologics X 3DCC 2026 calls upon scientists, innovators, and leaders to help ...
Not long ago, solving the crystal structure of a protein required an entire PhD. Growing crystals, collecting X-ray diffraction data, and interpreting electron density maps often took years of ...
Fapon Biopharma, a biotech in developing therapeutic biologics including cytokine-antibody fusion proteins and T-cell engagers, announced the publication of pioneering research on FP008, a novel ...
SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter referred to ...
Learn about women in STEM and the vital role of Dr Lidia Serina in advancing biopharma therapies and empowering women.
The U.S. Food and Drug Administration (FDA) announced on Wednesday (October 29) a plan to streamline the approval process for biosimilars, which are generic versions of complex biological drugs. These ...
Huonslab files BLA for HYDIZYME™, targeting MFDS approval in 2026 for its recombinant human hyaluronidase using HyDIFFUZE™.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results